IL33 protein, human
AstraZeneca’s IL-33 Drug Shows Mixed Results in COPD Trials, Despite Phase 2 Setbacks
AstraZeneca, IL-33, COPD, tozorakimab, phase 2 trials, respiratory diseases
Actionable Insights Powered by AI
AstraZeneca, IL-33, COPD, tozorakimab, phase 2 trials, respiratory diseases